NCT06136936

A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

A Multicenter, Exploratory, Randomized, Double-Arm, 4-week Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: Click Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An exploratory, double-arm, 4-week study to explore the feasibility and acceptability of abbreviated treatment with CT-156 for people with Schizophrenia.

Detailed description

The purpose of the proposed study is to evaluate the overall effects of use of an abbreviated version of CT-156 (the Study App) in participants aged 18 years or older with schizophrenia.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DEVICE	CT-156-C-001	CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.

Timeline

• Start date: 2023-09-20
• Primary completion: 2024-01-18
• Completion: 2024-02-22
• First posted: 2023-11-18
• Last updated: 2025-05-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study